It will become easier to discover imaging biomarkers and identify digital surrogates for modern end-points in personalized therapies, thanks to a partnership between Sylvain Meloche – Principal Investigator within the signaling and cell growth research unit at the Institute for Research in Immunology and Cancer (IRIC) along with his team, and Imagia, an AI-driven personalized healthcare company.
Sylvain Meloche’s team will try to accurately distinguish different types of cancers using artificial intelligence solutions applied to tumor imaging.
- Source
- Institute for Research in Immunology and Cancer
- Language
- French
